Media.Player

Spp24 and Tumor Suppression

Technology Benefits

Highly specific, inexpensive, non-toxic native binding proteinReduce tumor growth in both subcutaneous and bone cavity environmentsGreater binding spectrum than another BMP-bindng protein, noggin, making it effective for more cancer typesMore is known about the spp24 binding site than that of nogginAmenable to bioengineering improvements

Technology Application

Bone metastasis therapeuticEmbedded into a collagen sponge for tumor site implantationInjected directly into the tumor site

Detailed Technology Description

UCLA innovators have demonstrated the use of a small protein, Spp24, to reduce tumor growth in an animal model of skeletal metastasis. Spp24 binds to bone morphogenetic proteins (BMPs), TGF-β, and other related proteins, which have been implicated in bone metastases associated with many cancer types. The researchers have shown that binding of Spp24 prohibits the binding of these growth factors to tumor cells and drastically reduces tumor growth in mice injected with human non-small cell lung carcinoma (NSCLC). They treated the animals with subcutaneous or direct tumor injections of NSCLC cells and Spp24 and measured substantially reduced tumor volumes for both delivery methods in the presence of Spp24. In fact, there was insufficient tumor mass following the Spp24 direct injection to permit quantitative analysis. In practice the material could be embedded into a collagen sponge to implant into the tumor site or injected directly.

Supplementary Information

Patent Number: US20130143811A1
Application Number: US13699288A
Inventor: Murray, Samuel S. | Murray, Elsa J. | Wang, Jeffrey C.
Priority Date: 25 May 2010
Priority Number: US20130143811A1
Application Date: 5 Feb 2013
Publication Date: 6 Jun 2013
IPC Current: A61K003817
US Class: 5140088 | 4350691 | 5140192 | 5140193 | 5140194 | 5140195 | 5140198
Assignee Applicant: The Regents of the University of California
Title: Tumor Suppression Compositions
Usefulness: Tumor Suppression Compositions
Summary: For treating or ameliorating a tumor (i.e. metastatic cancer or primary cancer; or a tumor in bone, a lung tumor, a liver tumor, a brain tumor, a spinal tumor, a breast cancer, a prostate cancer, or a tumor that manifests with osteoblastic and/or bone metastases) in a mammalian subject; and for suppressing or delaying tumor growth (claimed).

Industry

Disease Diagnostic/Treatment

Sub Category

Cancer/Tumor

Application No.

8962569

Others

State Of Development

The anti-tumor material has been successfully tested in the inventors' NSCLC animal model. It is ready to be developed into a clinically useful therapeutic

Background

The spine is the most common site of tumor metastases to bone. Many different cancer types metastasize to the spine with lung, prostate, breast, kidney, and gastrointestinal cancers accounting for the majority of spinal column tumors. Current therapies for these cancers in bone include hormone treatment, external beam radiation, radioisotopes, prophylactic surgery for osteolytic lesions, and small molecule administration. These approaches, however, are all limited by toxicity, specificity, the potential for adverse side effects, and cost. The development of new therapeutic agents could lengthen and improve the quality of life for cancer patients.

Tech ID/UC Case

21507/2010-272-0

Related Cases

2010-272-0

*Abstract

UCLA researchers have demonstrated that the addition of a bone matrix protein specifically reduces tumor growth in their relevant animal model

*Applications

• Bone metastasis therapeutic
• Embedded into a collagen sponge for tumor site implantation
• Injected directly into the tumor site

*IP Issue Date

Feb 24, 2015

*Principal Investigator

Name: Elsa Murray

Department:

Name: Elsa Murray

Department:

Name: Samuel Murray

Department:

Name: Samuel Murray

Department:

Name: Jeffrey Wang

Department:

Country/Region

USA